KRAS and non-small cell lung carcinoma: The most common oncogenic driver in NSCLC is the mutation of Kirsten rat sarcoma viral oncogene homolog (KRAS), exhibiting approximately 20–30% prevalence among Western countries and 10–15% among Asian countries (2).